Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Minority Interest (2016 - 2025)

Historic Minority Interest for Marimed (MRMD) over the last 13 years, with Q3 2025 value amounting to -$1.8 million.

  • Marimed's Minority Interest fell 535.71% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 535.71%. This contributed to the annual value of -$1.8 million for FY2024, which is 618.18% down from last year.
  • According to the latest figures from Q3 2025, Marimed's Minority Interest is -$1.8 million, which was down 535.71% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, Marimed's Minority Interest ranged from a high of -$569574.0 in Q1 2021 and a low of -$1.8 million during Q3 2025
  • In the last 5 years, Marimed's Minority Interest had a median value of -$1.6 million in 2022 and averaged -$1.5 million.
  • The largest annual percentage gain for Marimed's Minority Interest in the last 5 years was 539.02% (2022), contrasted with its biggest fall of 18284.3% (2022).
  • Quarter analysis of 5 years shows Marimed's Minority Interest stood at -$1.6 million in 2021, then grew by 3.33% to -$1.5 million in 2022, then dropped by 9.2% to -$1.6 million in 2023, then fell by 6.18% to -$1.8 million in 2024, then decreased by 4.39% to -$1.8 million in 2025.
  • Its Minority Interest was -$1.8 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$1.8 million in Q1 2025.